1. LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B. (23rd April 2019) Authors: Fangusaro, Jason; Onar-Thomas, Arzu; Poussaint, Tina Young; Wu, Shengjie; Ligon, Azra H; Lindeman, Neal; Banerjee, Anu; Packer, Roger J; Kilburn, Lindsay B; Goldman, Stewart; Pollack, Ian F; Jakacki, Regina I; Qaddoumi, Ibrahim; Fisher, Paul G; Dhall, Girish; Baxter, Patricia; Kreissman, Susa G; ... Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 2 Page Start: ii98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN). Issue 2 (22nd June 2018) Authors: Gross, Andrea; Wolters, Pamela; Baldwin, Andrea; Dombi, Eva; Fisher, Michael J; Weiss, Brian; Kim, AeRang; Blakeley, Jaishri; Whitcomb, Patricia; Holmblad, Marielle; Maritin, Staci; Roderick, Marie Claire; Paul, Scott M; Therrien, Janet; Heisey, Kara; Doyle, Austin; Smith, Malcolm; Glod, John; St... Journal: Neuro-oncology Issue: Volume 20:Issue 2(2018)supplement 2 Page Start: i143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer. Issue 2 (13th December 2019) Authors: Myers, Andrea P.; Konstantinopoulos, Panagiotis A.; Barry, William T.; Luo, Weixiu; Broaddus, Russell R.; Makker, Vicky; Drapkin, Ronny; Liu, Joyce; Doyle, Austin; Horowitz, Neil S.; Meric‐Bernstam, Funda; Birrer, Michael; Aghajanian, Carol; Coleman, Robert L.; Mills, Gordon B.; Cantley, Lewis C.... Journal: International journal of cancer Issue: Volume 147:Issue 2(2020) Page Start: 413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. (17th April 2017) Authors: Galanina, Natalie; Smith, Sonali M.; Liao, Chuanhong; Petrich, Adam; Libao, Bernadette; Gartenhaus, Ronald; Westin, Jason R.; Cohen, Kenneth S.; Knost, James A.; Stadler, Walter M.; Doyle, Austin; Karrison, Theodore; Gordon, Leo I.; Evens, Andrew M. Journal: British journal of haematology Issue: Volume 181:Number 2(2018) Page Start: 264 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗